197368-49-3

Basic information

• Product Name: 5-(4-Aminophenyl)-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-8-one
• CAS NO: 197368-49-3
• Molecular Formula: C₁₆H₁₃N₃O₃
• Molecular Weight: 295.30031
• Mol File: 197368-49-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 5-(4-Aminophenyl)-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-8-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-Aminophenyl)-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-8-one(197368-49-3)
• EPA Substance Registry System: 5-(4-Aminophenyl)-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-8-one(197368-49-3)

Safety Data

• Hazardous Substances Data: 197368-49-3(Hazardous Substances Data)

Upstream product

• 207238-95-7 {6-[4-(2,2,2-Trifluoro-acetylamino)-benzoyl]-benzo[1,3]dioxol-5-yl}-acetic acid methyl ester 
• 194729-10-7 7,8-methylenedioxy-1-(4-nitrophenyl)-3,5-dihydro-2,3-benzodiazepin-4(4H)-one 
• 326-59-0 benzo[1,3]dioxol-5-yl-acetic acid methyl ester 
• 404-26-2 4-(trifluoroacetamido)benzoic acid 
• 457-52-3 4-(2,2,2-trifluoro-acetylamino)-benzoyl chloride 
• 2861-28-1 1,3-benzodioxole-5-acetic acid 
• 197369-14-5 2-(4-nitrobenzoyl)-4,5-methylenedioxyphenylacetic acid methyl ester 

Relevant articles and documents

SUBSTITUTED 2,3-BENZODIAZEPIN-4-ONES AND THE USE THEREOF

The invention relates to substituted 2,3-benzodiazepin-4-ones which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS

SUBSTITUTED 2,3-BENZODIAZEPIN-4-ONES AND THE USE THEREOF

The invention relates to substituted 2,3-benzodiazepin-4-ones which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, CMV retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition enhancers. The invention also is directed to the process for the preparation of the substituted 2,3-benzodiazepin-4-ones.

7,8-methylenedioxy-4H-2,3-benzodiazepin-4-ones as novel AMPA receptor antagonists

The synthesis and anticonvulsant activity of novel 7,8-methylenedioxy- 4H-2,3-benzodiazepin-4-ones 3a-e, structurally-related to GYKI 52466 1, a well-known noncompetitive AMPA-receptor antagonist, are reported. The new compounds possess marked anticonvuls